High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer: Treatment Evolution and Mature Results


      To report the clinical outcome of high-dose-rate (HDR) interstitial (IRT) brachytherapy (BRT) as sole treatment (monotherapy) for clinically localized prostate cancer.

      Methods and Materials

      Between January 2002 and December 2009, 718 consecutive patients with clinically localized prostate cancer were treated with transrectal ultrasound (TRUS)-guided HDR monotherapy. Three treatment protocols were applied; 141 patients received 38.0 Gy using one implant in 4 fractions of 9.5 Gy with computed tomography-based treatment planning; 351 patients received 38.0 Gy in 4 fractions of 9.5 Gy, using 2 implants (2 weeks apart) and intraoperative TRUS real-time treatment planning; and 226 patients received 34.5 Gy, using 3 single-fraction implants of 11.5 Gy (3 weeks apart) and intraoperative TRUS real-time treatment planning. Biochemical failure was defined according to the Phoenix consensus, and toxicity was evaluated using Common Toxicity Criteria for Adverse Events version 3.


      The median follow-up time was 52.8 months. The 36-, 60-, and 96-month biochemical control and metastasis-free survival rates for the entire cohort were 97%, 94%, and 90% and 99%, 98%, and 97%, respectively. Toxicity was scored per event, with 5.4% acute grade 3 genitourinary and 0.2% acute grade 3 gastrointestinal toxicity. Late grade 3 genitourinary and gastrointestinal toxicities were 3.5% and 1.6%, respectively. Two patients developed grade 4 incontinence. No other instance of grade 4 or greater acute or late toxicity was reported.


      Our results confirm IRT-HDR-BRT is safe and effective as monotherapy for clinically localized prostate cancer.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Potters L.
        • Morgenstern C.
        • Calugaru E.
        • et al.
        12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
        J Urol. 2005; 173: 1562-1566
        • Zelefsky M.J.
        • Kuban D.A.
        • Levy L.B.
        • et al.
        Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
        Int J Radiat Oncol Biol Phys. 2007; 67: 327-333
        • Kuban D.
        • Tucker S.
        • Dong L.
        • et al.
        Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
        • Galalae R.M.
        • Martinez A.
        • Mate T.
        • et al.
        Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1048-1055
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
        Cancer. 2002; 95: 281-286
        • Demanes D.J.
        • Rodriguez R.R.
        • Schour L.
        • et al.
        High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1306-1316
        • Pollack A.
        • Zagars G.K.
        • Starkschall G.
        • et al.
        Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105
        • Brenner D.J.
        • Martinez A.A.
        • Edmundson G.K.
        • et al.
        Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
        Int J Radiat Oncol Biol Phys. 2002; 52: 6-13
        • Fowler J.
        • Chappell R.
        • Ritter M.
        Is alpha/beta for prostate tumors really low?.
        Int J Radiat Oncol Biol Phys. 2001; 50: 1021-1031
        • Nath R.
        • Bice W.S.
        • Butler W.M.
        • et al.
        AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137.
        Med Phys. 2009; 36: 5310-5322
        • Milickovic N.
        • Mavroidis P.
        • Tselis N.
        • et al.
        4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery.
        Med Phys. 2011; 38: 4982-4993
        • Martinez A.A.
        • Demanes J.
        • Vargas C.
        • et al.
        High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
        Am J Clin Oncol. 2010; 33: 481-488
        • Mark R.
        • Anderson P.
        • Akins R.
        Interstitial high-dose-rate brachytherapy as monotherapy for early stage prostate cancer: median 8-year results in 301 patients.
        Brachytherapy. 2010; 9 ([abstract]): 76
        • Yoshioka Y.
        • Konishi K.
        • Sumida I.
        • et al.
        Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions.
        Int J Radiat Oncol Biol Phys. 2011; 80: 469-475
        • Hoskin P.
        • Rojas A.
        • Lowe G.
        • et al.
        High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.
        Int J Radiat Oncol Biol Phys. 2012; 82: 1376-1384
        • Ghilezan M.
        • Martinez A.
        • Gustafson G.
        • et al.
        High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data.
        Int J Radiat Oncol Biol Phys. 2012; 83: 927-932
        • Demanes D.J.
        • Martinez A.A.
        • Ghilezan M.
        • et al.
        High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2011; 81: 1286-1292
        • Barkati M.
        • Williams S.G.
        • Foroudi F.
        • et al.
        High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial.
        Int J Radiat Oncol Biol Phys. 2012; 82: 1889-1896
        • Rogers C.L.
        • Alder S.C.
        • Rogers R.L.
        • et al.
        High dose brachytherapy as monotherapy for intermediate risk prostate cancer.
        J Urol. 2012; 187: 109-116
        • Prada P.J.
        • Jimenez I.
        • González-Suárez H.
        • et al.
        High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results.
        Brachytherapy. 2012; 11: 105-110
        • Zelefsky M.J.
        • Leibel S.A.
        • Gaudin P.B.
        • et al.
        Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
        Int J Radiat Oncol Biol Phys. 1998; 41: 491-500
        • Martin T.
        • Baltas D.
        • Kurek R.
        • et al.
        3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
        Strahlenther Onkol. 2004; 180: 225-232
        • Karabis A.
        • Giannouli S.
        • Baltas D.
        HIPO: a hybrid inverse treatment planning optimization algorithm in HDR brachytherapy.
        Radiother Oncol. 2005; 76: 29
        • Roach M.
        • Hanks G.
        • Thames H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Skazikis G.
        • Kurek R.
        • Baltas D.
        Acute toxicity of HDR-brachytherapy as monotherapy for low-risk cancer: analysis of 297 patients treated with two different fractionation schemes [abstract].
        Strahlenther Onkol. 2007; 183: 125


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.